Literature DB >> 23397225

TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.

Shanglei Ning1, Nan Liang, Bin Liu, Xin Chen, Qi Pang, Tao Xin.   

Abstract

Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein which is associated with tumor development and progression in a variety of epithelial carcinomas, while its expression and role in gliomas have not been considered. The aim of the study was to investigate TROP2 expression in malignant gliomas with different World Health Organization (WHO) classification and its correlation with tumor proliferation and angiogenesis. Immuohistochemistry was used to determine TROP2 and Ki-67 expression and microvessel density (MVD) in tumor specimens and normal brain tissues from 69 glioma patients and the relationship between TROP2 and Ki-67 and MVD was investigated. Immunohistochemistry results showed that the TROP2 expression was found in 59 (85.5 %) of the 69 tumor specimens, but no expression in normal brain tissues. Furthermore, TROP2 expression is significantly higher in WHO grade III (P = 0.025) and WHO grade IV (P = 0.011) gliomas than in WHO grade II gliomas. TROP2 expression correlates with Ki-67 (r = 0.676, P = 0.012) and MVD (r = 0.365, P = 0.035), but not with gender or age in human gliomas. These results suggested that the TROP2 correlated with malignancy, proliferation and angiogenesis in human gliomas. This is the first study describing TROP2 expression in gliomas and its proliferation and angiogenesis-related characteristic may serve as a potential therapeutic target for glioma treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23397225     DOI: 10.1007/s10072-013-1326-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  35 in total

1.  Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Matthias Preusser; Harald Heinzl; Ellen Gelpi; Katharina Schonegger; Christine Haberler; Peter Birner; Christine Marosi; Monika Hegi; Thierry Gorlia; Johannes A Hainfellner
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

2.  Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.

Authors:  A M Ralte; M C Sharma; A K Karak; V S Mehta; C Sarkar
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.

Authors:  Yun-feng Shan; Yuan-lan Huang; Yuan-kang Xie; Yan-he Tan; Bi-Cheng Chen; Men-tao Zhou; Hong-qi Shi; Zheng-ping Yu; Qi-tong Song; Qi-yu Zhang
Journal:  Med Oncol       Date:  2010-06-23       Impact factor: 3.064

Review 4.  Inflammation meets cancer, with NF-κB as the matchmaker.

Authors:  Yinon Ben-Neriah; Michael Karin
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

5.  Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.

Authors:  Szilvia Mosolits; Katja Markovic; Jan-Erik Frödin; Lena Virving; Carl G M Magnusson; Michael Steinitz; Jan Fagerberg; Håkan Mellstedt
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 6.  Angiogenesis and invasion in gliomas.

Authors:  Lorenzo Bello; Carlo Giussani; Giorgio Carrabba; Mauro Pluderi; Francesco Costa; Andreas Bikfalvi
Journal:  Cancer Treat Res       Date:  2004

Review 7.  Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

8.  Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.

Authors:  Ping Guo; Bo Hu; Weisong Gu; Li Xu; Degui Wang; Hui-Jen Su Huang; Webster K Cavenee; Shi-Yuan Cheng
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

9.  Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.

Authors:  Rafael Cubas; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer       Date:  2010-09-21       Impact factor: 27.401

10.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer.

Authors:  D Fong; P Moser; C Krammel; J M Gostner; R Margreiter; M Mitterer; G Gastl; G Spizzo
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  9 in total

1.  Overexpression of EpCAM and Trop2 in pituitary adenomas.

Authors:  Xin Chen; Bo Pang; Yu Liang; Shang-Chen Xu; Tao Xin; Hai-Tao Fan; Yan-Bing Yu; Qi Pang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 2.  Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.

Authors:  Anna Shvartsur; Benjamin Bonavida
Journal:  Genes Cancer       Date:  2015-03

Review 3.  Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis.

Authors:  Ping Zeng; Min-Bin Chen; Li-Na Zhou; Min Tang; Chao-Ying Liu; Pei-Hua Lu
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

4.  Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways.

Authors:  Hongyu Guan; Zejun Guo; Weiwei Liang; Hai Li; Guohong Wei; Lijuan Xu; Haipeng Xiao; Yanbing Li
Journal:  BMC Cancer       Date:  2017-07-14       Impact factor: 4.430

5.  The role of tacstd-2 level in hepatitis C patients (controlled clinical research).

Authors:  Memduh Sahin; Aylin Yetim; Fehmi Ates
Journal:  Libyan J Med       Date:  2019-12       Impact factor: 1.657

Review 6.  Trop2: Jack of All Trades, Master of None.

Authors:  Sára Lenárt; Peter Lenárt; Jan Šmarda; Ján Remšík; Karel Souček; Petr Beneš
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

7.  High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.

Authors:  Jinhan Xie; Christina Mølck; Sophie Paquet-Fifield; Lisa Butler; Erica Sloan; Sabatino Ventura; Frédéric Hollande
Journal:  Oncotarget       Date:  2016-07-12

8.  Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.

Authors:  Lianhua Zhang; Guoliang Yang; Ruiyun Zhang; Liang Dong; Haige Chen; Juanjie Bo; Wei Xue; Yiran Huang
Journal:  Int J Oncol       Date:  2018-05-30       Impact factor: 5.650

9.  TROP2 methylation and expression in tamoxifen-resistant breast cancer.

Authors:  Stephanie M Zimmers; Eva P Browne; Kristin E Williams; Rahul M Jawale; Christopher N Otis; Sallie S Schneider; Kathleen F Arcaro
Journal:  Cancer Cell Int       Date:  2018-07-06       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.